Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

The TERTIO trial will propose to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine (UCPVax) with anti-PD-L1 therapy (atezolizumab) and bevacizumab in unresectable HCC by evaluation of the objective response rate at 6 months (randomized phase II, 10 centers, 105 patients)

Trial Details

NCT ID
NCT05528952
Phase
PHASE2
Sponsor
Centre Hospitalier Universitaire de Besancon
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Atezolizumab
  • Bevacizumab
  • UCPVax
Locations (sample)
  • Besançon, France|47.24878,6.01815
  • Chalon-sur-Saône, France|46.78112,4.85372
  • Créteil, France|48.79266,2.46569
  • Dijon, France|47.31344,5.01391
  • Montbéliard, France|47.50957,6.79823

Key Eligibility Criteria

  • Signed informed consent
  • Histologically confirmed hepatocellular carcinoma
  • Locally advanced, metastatic, or unresectable disease
  • Patient who had not previously received systemic anti-cancer treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →